Utilization of Poly(ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer: A Retrospective Cohort Study of US Healthcare Claims Data.

Multivariable models stratified for the presence of a relevant CEI at baseline and adjusted for index PARPi regimen, CCI score, prior treatment with bevacizumab, and cancer-related surgery during the baseline period confirmed that there was a significantly greater probability of any CEI in the follow-up period with niraparib than with olaparib (HR 1.35, 95% CI 1.14–1.59; P = 0.0005); the difference in probability of experiencing any CEI between rucaparib and olaparib (HR 1.16, 95% CI 0.94–1.43; P = 0.16) and niraparib and rucaparib (HR 1.16, 95% CI 0.95–1.41; P = 0.15) did not reach statistical significance (Supplementary Table 4 and Supplementary Fig. 3).

also in 111,027 other papers